TEHRAN, June 30 (MNA) – Research Institute of Nuclear Science and Technology of the Atomic Energy Organization of Iran (AEOI) has developed radiopharmaceuticals in collaboration with President’s science and technology deputy.
The Islamic Republic of Iran has worked to gain command in using nuclear technology through investments in peaceful technologies including production of radiopharmaceuticals and energy to meet domestic needs in line with Development and Vision Plan for the future 20 years. These attempts made Iran a leading country in the region in the field, despite the cruel sanctions hitting its economy and imports of foreign pharmaceuticals.
Amir Reza Jalilian, a researcher of Radiopharmaceutical Research and Development Lab (RRDL) ,Nuclear Science and Technology Research Institute told Mehr News the developed radiopharmaceuticals had immediately clinically successfully tested and sent to the Ministry of Health to be given necessary production permits by the Ministry’s Ethics Committee. “Only after the process completed, had the radiopharmaceuticals been distributed to pharmacies across the country,” he said, “the producer had not merely produced radiopharmaceuticals; rather, it had planned for commercialization of the products in line with the President’s science and technology deputy.”
“The special view, along with close cooperation of Minister of Health, helped development and production of 15 radiopharmaceuticals; two other radiopharmaceuticals are under process of being introduced to country’s health sector,” Jalilian added.
The Iran Project is not responsible for the content of quoted articles.